CAR-T Cell Therapy and Beyond

CAR-T Cell Therapy and Beyond
Developing the future of CAR-T cell therapy today
Novartis is pioneering the way in the class of cell and gene treatment and has developed the first CAR-T cell therapy approved for paediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (ALL). This heritage includes setting the standard in patient and caregiver support, safety and efficacy, access, and partnerships with healthcare institutions, local health authorities, and academic institutions around the world.
![Image of CAR-T cells latching on to cancer cells] Image of CAR-T cells latching on to cancer cells]](https://www.novartis.com/sites/www.novartis.com/files/styles/landing_page_1600x800/public/what-is-cat-t-cell-therapy-image.jpg?itok=b5OhJcN8)
What is CAR-T Cell Therapy?
CAR-T cell therapy is a cutting-edge immunotherapy that uses specifically altered cells from your immune system to fight cancer in your blood. Currently, CAR-T is approved for patients with certain blood cancers.

Patients and Caregivers
This page includes information for patients and caregivers about CAR-T cell therapy, the treatment process, who can benefit from this therapy, and what makes CAR-T cell therapy different from other treatment options.

Healthcare Professionals
This page includes information for healthcare professionals about the science, process, landscape, and pioneers of CAR-T cell therapy.
We need to reimagine medicine, because the world and patients need us to.
A patient’s journey with CAR-T cell therapy explained.
References:
- Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) [press release]. Basel, Switzerland. Novartis Pharma AG; August 27, 2018.
- Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2018.
- Novartis. Novartis Annual Review. Novartis Pharma AG. Accessed April 22, 2019. Novartis Annual Review 2018 (PDF 12.4 MB).